BMC Anesthesiology

, 18:142 | Cite as

Effect of Shenmai injection on cognitive function after cardiopulmonary bypass in cardiac surgical patients: a randomized controlled trial

  • Lei Chen
  • Liangrong Wang
  • Qian Zhuo
  • Qiong Zhang
  • Feifei Chen
  • Liling Li
  • Lina Lin
Open Access
Research article
Part of the following topical collections:
  1. Perioperative medicine and outcome



Postoperative cognitive dysfunction (POCD) is a common complication after cardiac surgery that influences the clinical outcomes and quality of life of patients. This study aimed to evaluate the effects of Shenmai injection (SMI) on POCD of patients who underwent cardiac valve replacement under cardiopulmonary bypass (CPB).


This prospective, randomized, controlled trial was conducted from September 2014 to January 2017. Eighty-eight patients receiving cardiac valve replacement under CPB were randomized into the control (C) or the SMI (S) group. SMI (0.6 mL/kg) was administered intravenously from the time of anesthesia induction to the beginning of CPB. Cognitive function was assessed at 3 days before surgery and 3 days, 7 days, and 1 month after surgery using the Beijing version of the Montreal Cognitive Assessment (MoCA-BJ) score. The serum levels of neuroglobin (Ngb), hypoxia-inducible factor-1α (HIF-1α), and neuron-specific enolase (NSE) were measured at 30 min after induction (T0), immediately after the endonasal temperature rewarmed to 36 °C (T1), and 1 h (T2), 6 h (T3), 24 h (T4), 48 h (T5), and 72 h (T6) after CPB.


Compared with the baseline values at T0, the serum Ngb levels in group C were significantly decreased at T1–2 and then increased at T3–6, while the levels in group S were decreased at T1–2 and increased at T4–6, compared to group C (p < 0.05). The serum HIF-1α levels at T1–4 and the serum NSE levels at T1–6 were significantly increased in both groups (p < 0.05). The serum levels of Ngb at T3, HIF-1α at T1–3, and NSE at T3–4,6 were lower in group S, compared to group C (p < 0.01). The MoCA-BJ scores were decreased at 3 and 7 days after surgery in both groups, and the MoCA-BJ scores in group S were higher than those in group C at 3 and 7 days after surgery (p < 0.01).


Cognitive function is impaired postoperatively in patients who have undergone cardiac valve replacement under CPB. In addition, treatment with the traditional Chinese medicine SMI decreases the serum levels of Ngb, HIF-1α, and NSE as well as attenuates cognitive dysfunction.

Trial registration

This trial was registered with as ChiCTR-TRC-14004373 on March 11, 2014.


Cardiopulmonary bypass Cognitive dysfunction Shenmai injection Cerebral protection 



Coronary Care Unit


Cardiopulmonary bypass


Hypoxia-inducible factor-1α


Beijing version of the Montreal Cognitive Assessment




Neuron-specific enolase


Postoperative cognitive dysfunction


Regional cerebral oxygen saturation


Shenmai Injection


Postoperative cognitive dysfunction (POCD) is considered as a common complication of cardiovascular surgery and causes several adverse effects, such as a delayed long-term recovery, a reduced quality of life, and an increased mortality rate [1, 2]. Cerebral embolization, systemic inflammatory response, and low cerebral oxygenation to cerebral hypoperfusion are usually implicated as potential factors for short-term POCD after cardiac surgery [3, 4]. In addition, oxygenation and upregulation of neuroglobin (Ngb) and hypoxia-inducible factor-1α (HIF-1α) expression have been considered as a protective mechanism responding to ischemic injury to neurons, while neuron-specific enolase (NSE) is a marker of neuronal damage. Therefore, the circulating levels of Ngb, HIF-1α, and NSE have been used as indicators for cerebral injury [5, 6]. However, whether circulating Ngb, HIF-1α, and NSE levels could serve as early indicators for cognitive dysfunction after cardiac surgery has not been reported.

With the increasing understanding of the mechanisms involved, various treatments have been introduced over the last decade. Shenmai injection (SMI), a Chinese traditional medicine mainly consisting of the two herbal components Radix ginseng Rubra and Radix ophiopogonis, is extensively used in China as an organ protector [7]. Our previous studies [7, 8, 9, 10] have demonstrated the protective effects of SMI against oxidative injury and the inflammatory response, showing its potential as a therapeutic agent for the prevention of lung injury after cardiopulmonary bypass (CPB). However, reports concerning the effects of SMI on cognitive function in patients undergoing cardiac valve replacement under CPB are not available.

Therefore, this prospective, randomized, controlled trial was designed to evaluate the predictive effects of serum Ngb, HIF-1α, and NSE on POCD after CPB as well as the protective effect provided by SMI administration in patients undergoing cardiac valve replacement under CPB. The Beijing version of the Montreal Cognitive Assessment (MoCA-BJ; range, 0–30) was analyzed for assessing the cognitive function; and blood gas parameters of the jugular veins as well as Ngb, HIF-1α, and NSE expression levels were used to evaluate cerebral injury.


Study design and patients

This prospective, randomized, controlled trial was conducted from September 2014 to January 2017 at the First Affiliated Hospital of Wenzhou Medical University. This trial was registered with as ChiCTR-TRC-14004373 on March 11, 2014. After approval by the hospital’s Clinical Research Ethics Committee and written informed consent from the patients, 90 patients receiving cardiac valve replacement under CPB were screened. This study was reported according to the CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration checklist [11].

Inclusion criteria included American Society of Anesthesiologists physical status II–III, aged 40–69 years old, body mass index of 18–29 kg/m2, left ventricular ejection fraction ≥0.3, and preoperative MoCA-BJ score ≥ 26. Patients were excluded from this study if they had a diagnosis of diabetes mellitus, hypertension, peripheral vascular disease, pulmonary disease, neurological disease, mental disorder, renal insufficiency, liver dysfunction, infective endocarditis, or previous coronary heart disease before screening. In addition, patients who received SMI treatment within 6 months were also excluded.

Surgical interventions

At 30 min before surgery, 0.2 mg/kg morphine and 0.3 mg/kg scopolamine were given intramuscularly. After a standard monitor was attached, a peripheral venous access was secured. Before induction, a 20-G arterial catheter was cannulated, and the sensor/transducer (FloTrac) was connected to record the waveform. Anesthesia was induced intravenously with 0.01 mg/kg midazolam, 0.6 μg/kg sufentanil, 0.3 mg/kg etomidate, and 0.15 mg/kg vecuronium bromide, and then tracheal intubation was facilitated. The patients received intermittent positive-pressure ventilation with a tidal volume of 8–10 mL/kg and a respiratory rate of 10 beats per min to maintain the end-tidal carbon dioxide pressure at approximately 35 mmHg. Continuous administration of sevoflurane and propofol combined with intermittent injection of sufentanil and vecuronium were used to maintain the depth of anesthesia, which was monitored by the bispectral index. After anesthesia, the right internal jugular vein was reversely cannulated to the bulbar level for continuous blood sampling.

All patients received standard CPB management. CPB was instituted with a membrane oxygenator. The body temperature was maintained under mild hypothermia (32–33 °C), and α-stat was used for acid-base management. The pump flow was maintained at a rate of 2.0–2.5 L/min/m2 using a nonpulsatile flow, and a blood cardioplegic solution was used. During the perioperative period including CPB, the mean arterial blood pressure was maintained at 55–80 mmHg using norepinephrine or vasopressin. Milrinone was used if the left ventricular ejection fraction was less than 30% after CPB, as measured by transesophageal echocardiography, in case of right ventricular dysfunction or pulmonary hypertension. A blood transfusion was needed if the hematocrit level fell below 21% during CPB or below 25% during the remaining perioperative period. Fresh frozen plasma was transfused when the international normalized ratio was greater than 1.5 with excessive bleeding greater than 200 mL/h for two consecutive hours in the postoperative period. Platelet concentrates were transfused when the platelet count was less than 50,000/mm3 with excessive bleeding greater than 200 mL/h for two consecutive hours in the postoperative period. All patients were transferred to the Coronary Care Unit (CCU) after surgery and received standard management according to institutional guidelines by the CCU staff.

SMI administration

SMI composed of Radix ginseng Rubra and Radix Ophiopogonis was a product of Sanjiu Pharmaceutical Co. Ltd. (Yaan, China; batch No. Z51021845, provided as 1 g of crude drug in an ampoule of 10 mL). In group S, SMI at a dose of 0.6 mL/kg, dissolved in 250 mL of normal saline, was administered intravenously from the time of anesthesia induction to the beginning of CPB at a rate of 10 mL/min. The control patients were given an equal volume of normal saline instead.

Outcome measures

The durations of aortic cross clamping, CPB, and anesthesia maintenance were recorded, respectively. The hemodynamic parameters, including the mean arterial blood pressure and heart rate, as well as the blood gas parameters of the jugular veins, which included the jugular venous oxygen saturation (SJvO2), jugular venous oxygen partial pressure (PJvO2), hemoglobin, hematocrit, and lactic acid (Lacjv) of the jugular venous blood samples, were collected at 30 min after induction (T0), immediately after the endonasal temperature rewarmed to 36 °C (T1), the end of cardiac surgery (T2), and 6 h (T3), 24 h (T4), 48 h (T5), and 72 h (T6) after CPB, respectively. The MoCA-BJ scores were evaluated at 3 days before surgery as well as 3 days, 7 days, and 1 month after surgery.

The remaining blood sample was centrifuged to separate the serum, which was then stored at − 20 °C for subsequent analyses of Ngb, HIF-1α, and NSE. Indicators were determined using commercially available enzyme-linked immunosorbent assay kits (Westang Biotechnology Co. Ltd., Shanghai, China), according to the manufacturer’s instructions. The levels of these indicators were measured by investigators unaware of the group allocation and the blood gas results.

Sample size calculation and randomization

The sample size was planned and calculated according to comparison of the MoCA-BJ on the third and seventh day postsurgery. With a power of 66% and a significance level of 5%, a total of 17 patients would be required in each group to make a difference of − 3.4 in the MoCA-BJ on the third day postsurgery, with a dropout rate of 10%. With a power of 31% and a significance level of 5%, a total of 28 patients would be required in each group to make a difference of − 1.7 in the MoCA-BJ on the seventh day postsurgery, with a dropout rate of 10%. Thus, enrollment of 88 patients was planned to minimize statistical errors.

Patients were randomized using a sealed envelope system. Eighty-eight patients were randomized to either the SMI (group S, 44 cases) or the control (group C, 44 cases) group. The medical staff collecting and analyzing the MoCA-BJ scores was blinded to the treatment allocation.

Statistical analysis

Data were tested for normal distribution using the Kolmogorov–Smirnov test. Continuous, normally distributed data were expressed as the mean ± standard deviation. Categorical data were expressed as numbers. Data on the block level were expressed as a median (range) and analyzed with the Mann–Whitney test. For comparison of demographic and operative data, categorical data were compared with the χ2 test and quantitative data were compared with the Student’s t-test. For comparison of outcomes within the same group at different time points, data were analyzed by repeated-measures analysis of variance using the Bonferroni method. For comparison of outcomes between different groups at the same time point, the paired t-test was conducted. A P value < 0.05 was considered significant. Analysis was performed using SPSS software, version 17.0 for Windows.


Patient enrollment and characteristics

The study flow diagram is shown in Fig. 1. A total of 80 patients completed the study. No significant differences between the two groups were found in terms of the clinical characteristics, including gender, age, body mass index, surgical procedure type, duration of aortic cross clamping, CPB, and anesthesia maintenance (p > 0.05) (Table 1).
Fig. 1

CONSORT 2010 Flow Diagram

Table 1

Clinical Characteristics of Patients (n = 40 in Each Group)


Group C

Group S

Gender (M/F)



Age (yr)

55 ± 10

58 ± 9

Body mass index (kg/m2)

23.0 ± 2.8

24.2 ± 2.4

Valve replacement(n)

 single valve replacement



 double valve replacement



Duration of ACC (min)

89 ± 21

86 ± 20

Duration ofCPB(min)

116 ± 22

111 ± 24

Duration of anesthesiamaintenance (min)

247 ± 33

239 ± 29

ACC aortic cross clamp, CPB cardiopulmonary bypass

Data are presented as mean ± SD, or numbers

Hemodynamic parameters

In comparison to T0, the mean arterial blood pressure was decreased at T1 (p < 0.001) and increased at T4,6 (p = 0.005 and p = 0.041) in group C, while it was decreased at T1,3 (p < 0.001 and p = 0.021) and increased at T4–6 (p = 0.002, p = 0.002, and p = 0.006) in group S. The heart rate was significantly decreased at T1 and increased at T2–6 in both groups (p < 0.001). There were no differences in hemodynamic variables (mean arterial blood pressure and heart rate) at any time points (p > 0.05) between these two groups (Table 2).
Table 2

MAP and HR (n = 40 in Each Group)












73 ± 10

60 ± 6*

71 ± 9

71 ± 8

83 ± 8*

80 ± 9

80 ± 9

(mm Hg)


74 ± 7

62 ± 6*

71 ± 8

69 ± 5

81 ± 9*

83 ± 9*

80 ± 6*



64 ± 13


86 ± 10*

91 ± 11*

81 ± 9*

85 ± 7*

80 ± 11*



62 ± 10


88 ± 10*

93 ± 9*

83 ± 11*

85 ± 7*

81 ± 10*

T0, 30 min after the induction; T1, immediately after temperature rewarmed to 36 °C; T2, end of cardiac surgery; T3–6, 6 h, 24 h, 48 h, 72 h after CPB

Data are expressed as mean ± SD

* p < 0.01 vs. T0.† p < 0.05 vs. T0

Blood gas analysis

Table 3 shows the blood gas parameters. Compared to the baseline values at T0, the levels of SJvO2 and PJvO2 were increased significantly at T2 (p = 0.001 and p < 0.001) in group C and T1–2 (p < 0.001) in group S; the values were much higher in group S at T1–3 than in group C (p < 0.001) (Fig. 2). The levels of Lacjv were increased at T1–4 (group C: p < 0.001, p < 0.001, p < 0.001, and p = 0.003 and group S: p < 0.001, p < 0.001, p < 0.001, and p = 0.002) and decreased at T6 (group C: p = 0.003; group S: p = 0.001) in both groups, compared with T0; however the level at T4 in group S was lower than that in group C (p < 0.001) (Fig. 2). The levels of hemoglobin and hematocrit were lower at T1–6 than at T0 (p < 0.001), but no differences were found between the two groups (p > 0.05).
Table 3

Blood Gas Parameters (n = 40 in Each Group)










SJ vO2


58.2 ± 12.6

48.4 ± 4.7*

64.3 ± 8.0*

54.7 ± 8.9

54.8 ± 5.4

50.7 ± 6.1*

53.3 ± 8.7



57.7 ± 8.8

70.5 ± 12.0*‡

75.8 ± 7.4*‡

59.9 ± 4.6

56.1 ± 3.8

52.1 ± 6.0*

50.8 ± 4.4*

PJ vO2


33.8 ± 8.1

29.5 ± 2.8*

40.1 ± 6.0*

32.1 ± 5.1

31.0 ± 2.5

28.3 ± 3.0*

29.7 ± 4.2



34.1 ± 3.9

45.7 ± 11.8*‡

50.4 ± 8.0*‡

34.6 ± 4.0

30.5 ± 2.1*

28.8 ± 3.1*

28.6 ± 2.5*



1.1 ± 0.5

1.7 ± 0.7*

1.9 ± 1.0*

2.1 ± 1.0*

2.0 ± 0.8*

1.0 ± 0.3

0.8 ± 0.3*



1.1 ± 0.5

1.7 ± 0.7*

1.9 ± 0.8*

1.9 ± 0.8*

1.4 ± 0.6*‡

1.0 ± 0.3

0.8 ± 0.3*



12.8 ± 1.4

8.1 ± 0.9*

9.5 ± 1.1*

10.5 ± 1.3*

11.1 ± 1.3*

9.9 ± 1.1*

9.8 ± 1.1*



13.0 ± 1.1

8.1 ± 0.7*

9.6 ± 1.0*

10.3 ± 0.9*

11.3 ± 0.9*

10.1 ± 1.3*

10.2 ± 1.4*



37.8 ± 4.1

24.0 ± 2.8*

28.0 ± 3.1*

30.9 ± 3.2*

32.5 ± 3.9*

29.2 ± 3.3*

28.7 ± 3.1*



38.1 ± 3.3

24.0 ± 1.9*

28.3 ± 3.0*

30.4 ± 2.6*

33.2 ± 2.7*

29.7 ± 3.9*

30.1 ± 4.0*

T0, 30 min after the induction; T1, immediately after temperature rewarmed to 36 °C; T2, end of cardiac surgery; T3–6, 6 h, 24 h, 48 h, 72 h after CPB

Data are expressed as mean ± SD

* p < 0.01 vs. T0.† p < 0.05 vs. T0.‡ p < 0.01 vs. group C

Fig. 2

Blood Gas Parameters

Concentrations of Ngb, HIF-1α, and NSE

Table 4 shows the serum levels of Ngb, HIF-1α, and NSE in both groups. Compared with T0, the levels of serum Ngb in group C were significantly decreased at T1–2 (p < 0.001 and p = 0.004) and significantly increased at T3–6 (p < 0.001), with two peaks at T3 and T6, respectively; while the levels in group S were significantly decreased at T1–2 (p < 0.001) and significantly increased at T4–6 (p = 0.023, p < 0.001 and p < 0.001), with the highest levels at T6. The levels of serum HIF-1α were increased at T1–4 and had peaks at T2 in both groups (group C: p < 0.001, p < 0.001, p < 0.001, and p = 0.001; group S: p = 0.001, p < 0.001, p < 0.001, and p = 0.023). The serum NSE levels in both groups were significantly increased at T1–6 (p < 0.001). The serum levels of Ngb at T3 (p < 0.001), HIF-1α at T1–3 (p < 0.001), and NSE at T3–4,6 (p < 0.001, p = 0.002, and p < 0.001) were lower in group S than in group C (Fig. 3).
Table 4

Serum Levels of Ngb, HIF-1α and NSE(n = 40 in Each Group)












1.23 ± 0.42

0.53 ± 0.19*

0.93 ± 0.43*

2.83 ± 1.14*

1.89 ± 0.77*

1.92 ± 0.83*

2.33 ± 0.74*



1.35 ± 0.39

0.61 ± 0.23*

0.93 ± 0.32*

1.20 ± 0.61

1.62 ± 0.59

1.94 ± 0.80*

2.35 ± 0.83*



2.01 ± 0.55

4.54 ± 1.38*

10.98 ± 2.55*

6.56 ± 2.06*

2.48 ± 0.99*

2.04 ± 0.62

2.33 ± 1.12



1.93 ± 0.68

2.37 ± 1.04*‡

9.11 ± 1.49*‡

4.69 ± 2.01*‡

2.36 ± 1.30

2.15 ± 0.90

1.98 ± 0.77



5.05 ± 1.21

18.47 ± 5.72*

34.93 ± 12.33*

40.77 ± 15.73*

14.25 ± 5.67*

9.54 ± 3.50*

12.27 ± 5.76*



5.28 ± 1.35

17.67 ± 5.51*

33.82 ± 12.78*

27.96 ± 6.53*‡

10.51 ± 4.94*‡

8.25 ± 3.61*

6.44 ± 1.35*‡

T0, 30 min after the induction; T1, immediately after temperature rewarmed to 36 °C; T2, end of cardiac surgery; T3–6, 6 h, 24 h, 48 h, 72 h after CPB

Data are expressed as mean ± SD

* p < 0.01 vs. T0.† p < 0.05 vs. T0.‡ p < 0.01 vs. group C

Fig. 3

Serum Levels of Ngb, HIF-1α and NSE

MoCA-BJ analysis

Compared to preoperative values at 3 days before surgery, the MoCA-BJ scores were decreased at 3 and 7 days after surgery in both groups (group C: p < 0.001; group S: p < 0.001, p = 0.001). The MoCA-BJ scores of group S were higher than those in group C at 3 and 7 days after surgery (p < 0.001) (Fig. 4). The scores of Clock, Naming, Memory, Serial 7, and Sentence rep in group C (p = 0.025, p < 0.001, p < 0.001, p < 0.001 and p = 0.015) and the score of Memory in group S (p = 0.012) were lower than the preoperative baseline values at 3 days after surgery. Compared to group C, the scores of Cube, Memory, Serial 7, and Sentence rep were elevated at 3 days after surgery in group S (p = 0.005, p = 0.005, p = 0.008, and p < 0.001) (Fig. 5).
Fig. 4

Total MoCA-BJ scores

Fig. 5

MoCA-BJ Items scores


Recent technological advances have contributed to an increasingly lower rate of clinically evident complications, but POCD remains an important clinical problem associated with cardiac surgery [12, 13]. Its manifestations may include impairment in visuospatial and executive functions, naming, attention, language, delayed recall (memory), and orientation [14]. Presently, the MoCA and the Mini-Mental State Examination (MMSE) are the most commonly used neuropsychological tests for POCD. As a simple cognitive screening tool, the MoCA-BJ was used in this study to balance the influences of various ages and education levels; [15] and its sensitivity and specificity are better than those of the MMSE [16, 17]. As shown in this study, the total MoCA-BJ scores were significantly lower at 3 and 7 days after surgery in patients receiving cardiac surgery in group C, and the scores basically recovered to baseline values at 1 month after surgery, suggesting that the patients suffered from POCD in the early but not the late stage after cardiac surgery. The results also showed that several cognitive domains, especially memory, were badly impaired; these results were identical to previous ones [18, 19]. For example, Yu et al. [16] have reported that among all the cognitive subdomains, delayed recall (Memory) was shown to be the best index to differentiate POCD from the normal controls. Similarly, Jones et al. [20] have reported that the severity of heart/circulation problems independently contributed to a worse delayed recall (Memory) performance. Our results showed that the Memory scores were lower than the baseline values at 3 days after surgery in both groups, but the scores in group S were improved after SMI administration. In addition, changes in the Clock, Naming, Serial 7, and Sentence rep scores were similar as the delayed recall evaluation, which were all lower than the preoperative baselines values.

Though the cognitive damages after cardiac surgery have been well described, the exact mechanisms involved have not been elucidated. Zheng et al. [21] have reported an association between decreased regional cerebral oxygen saturation (rScO2), desaturation, and POCD in adult patients receiving cardiac surgery. The blood flow of the internal jugular vein bulbar is mainly from the cerebral hemisphere, and the levels of SJvO2 and PJvO2 can indirectly reflect rScO2 [22, 23]. As shown in our study, compared to the baseline values, the levels of SJvO2 and PJvO2 were significantly decreased and the levels of Lacjv were increased in patients undergoing CPB, suggesting that cerebral anoxia may at least partly contribute to POCD.

Ngb, a novel neuroprotective protein, affords protection against hypoxia/ischemia and oxidative stress-induced injury in the nervous system. Ngb overexpression enhances cell survival under conditions of anoxia or oxygen and glucose deprivation [24], and it protects neurons against cerebral ischemia-reperfusion injury [25]. Previous data have implied that the upregulated expression of Ngb could be an endogenous compensatory or protective mechanism in response to sublethal hypoxic/ischemic insults to brain neurons, and Barzo et al. [26] have reported that a predominantly vasogenic edema formation occurred immediately after brain injury and a more widespread and slower cytotoxic edema formation resulted later, which may lead to two peaks of Ngb expression following brain injury. Furthermore, recent studies have found that the Ngb levels are increased in early and moderately advanced Alzheimer’s disease subjects [27]. These findings may explain the results uncovered in our study.

HIF-1α has emerged as a critical oxygen-sensitive transcription factor that orchestrates the body’s protective response to hypoxia and can protect organs against acute ischemic injury [28]. Moreover, it has been recently documented that the expression of HIF-1α under hypoxia has protective effects on astrocytes, thus playing an important role in cerebral protection [29]. Its protective effects also have been proven in a model of cultured cortical neurons exposed to moderate hypoxia [30, 31]. As shown in our study, the serum HIF-1α level began to increase before the Ngb level. The role of HIF-1α in the regulation of oxygen homeostasis in tissue may be correlated with Ngb expression [32]. Additionally, a recent study has demonstrated that HIF-1α contributes to the upregulation of Ngb expression under hypoxic conditions in mice [33]. However, further studies are necessary to elucidate the exact mechanisms of HIF-1α in Ngb regulation under hypoxic and other pathological conditions.

NSE, which was originally described by Moore and McGregor in 1965, [34] has been considered as a traditional marker to assess neuronal damage; [35] however, clinical trials have shown controversial results regarding the correlation between cognitive dysfunction and the circulating NSE level. Some studies have found a correlation between the NSE level and the clinical outcome of neurocognitive dysfunction, [36, 37, 38] but others have failed to do so [39, 40]. In our study, the serum NSE levels were significantly increased after CPB. Therefore, NSE may be an indicative parameter for POCD.

SMI, a traditional Chinese herbal medicine, is widely used in mainland China for the treatment of cardio/cerebrovascular disorders and as an adjunct therapy to tumor chemotherapy [41]. The active component of SMI is radix ginseng rubra, which contains Ginsenoside Rg3 and Ginsenoside Rb1. The protective effects of Ginsenoside Rb1 have been well proven in various models of cerebral ischemia-reperfusion injury [42, 43]. Its possible mechanism of the protective effect on the central nervous system involves calcium channel blockade, estrogen-like action, and antiperoxidation, which may inhibit cerebral nerve cell apoptosis and ameliorate mitochondrial dysfunction, etc [44]. Hence, we hypothesized that treatment with SMI might present beneficial effects against reperfusion injury and improve cognitive function after cardiac valve replacement under CPB. As shown in our study, even though the MoCA-BJ score in group S was decreased at 3 days after surgery but was still improved as compared to group C at the early stage after CPB, SMI treatment increased the levels of SJvO2 and PJvO2 as well as decreased the serum Ngb, HIF-1α, and NSE levels at different time points. These data implied that SMI may attenuate cerebral anoxia and neuronal damage, subsequently improving cognitive function and reducing the incidence of POCD.

Several limitations of this study should be noted. First, enrollment of patients did not consider the traditional Chinese medicine syndromes, and the lack of traditional Chinese medicine syndrome diagnosis during patient enrolment was another potential source of selection bias. Second, whether SMI exerts protective effects by improving cerebral oxygenation directly or by other implied mechanisms should be investigated in future studies. Finally, the optimal dosage of SMI and its main effective ingredient were not determined in the current study. Our future studies will address these issues.


In conclusion, cognitive function is impaired postoperatively in patients undergoing cardiac surgery with CPB. The novel biomarkers Ngb, HIF-1α, and NSE could serve as early indicators for POCD. Treatment with SMI, a traditional Chinese medicine, decreases the levels of serum Ngb, HIF-1α, and NSE, thus improving cognitive function.



The present study was granted by Wenzhou Municipal Science and Technology Bureau (No. H20100010).

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due to them containing information that could compromise research participant privacy, but might be made available from the corresponding author on reasonable request.

Authors’ contributions

LNL and LRW designed this study and wrote the manuscript. CL and LLL performed the experiments. QZ1 collected all data. QZ2 and FFC assisted with data analysis. All the authors approved the final version of the manuscript. CL and LRW were co-first authors and contributed equally to this study.

Ethics approval and consent to participate

This study was approved by the ethics committee of the First Affiliated Hospital of Wenzhou Medical University and written informed consent was obtained from all patients according to international guidelines.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.
    Tonkovic D, Marinic DK, Baronica R, Oberhofer D, Pavlovic DB, Peric M. Postoperative mental disorders in cardiovascular surgery. Acta Med Croatica. 2012;66:67–72.PubMedGoogle Scholar
  2. 2.
    Hartholt KA, van der Cammen TJ, Klimek M. Postoperative cognitive dysfunction in geriatric patients. Z Gerontol Geriatr. 2012;45:411–6. Scholar
  3. 3.
    Djaiani G, Katznelson R, Fedorko L, Rao V, Green R, Carroll J, Katski J. Early benefit of preserved cognitive function is not sustained at one-year after cardiac surgery: a longitudinal follow-up of the randomized controlled trial. Can J Anaesth. 2012;59:449–55. Scholar
  4. 4.
    Papadopoulos G, Karanikolas M, Liarmakopoulou A, Papathanakos G, Korre M, Beris A. Cerebral oximetry and cognitive dysfunction in elderly patients undergoing surgery for hip fractures: a prospective observational study. Open Orthop J. 2012;6:400–5. Scholar
  5. 5.
    Hota KB, Hota SK, Srivastava RB, Singh SB. Neuroglobin regulates hypoxic response of neuronal cells through Hif-1alpha- and Nrf2-mediated mechanism. J Cereb Blood Flow Metab. 2012 Jun;32(6):1046–60. Scholar
  6. 6.
    Yildirim AO, Eroglu M, Kaldirim U, Eyi YE, Simsek K, Durusu M, Yamanel L, Arziman I, Tuncer SK, Toygar M, Balkan A, Cayci T, Demirbas S, Oter S, Bilgi C. Serum neuron-specific enolase and S-100beta levels as prognostic follow-up markers for oxygen administered carbon monoxide intoxication cases. Indian J Biochem Biophys. 2015;52:29–33.PubMedGoogle Scholar
  7. 7.
    Wang L, Wang W, Zhao X, Jin L, Bai Y, Yao H, Zhuo Q, Lin L. Effect of Shenmai injection, a traditional Chinese medicine, on pulmonary dysfunction after tourniquet-induced limb ischemia-reperfusion. J Trauma. 2011;71:893–7. Scholar
  8. 8.
    Lin L, Wang L, Chen F, Hu M, Miao J, Wang J. Effect and significance of Shenmai injection on value of vascular endothelial active factors of heart valve replacement patients. Zhongguo Zhong Yao Za Zhi. 2009;34:1155–8.PubMedGoogle Scholar
  9. 9.
    Lin LN, Zhang SG, Wang WT, Xi JH, Qiu XX, Dai YY. Effect of Shenmai injection on expression and activity of heme oxygenase-1 in reperfusion injury after pulmonary ischemia in rabbits. Zhongguo Zhong yao za zhi. 2008;33:296–9.PubMedGoogle Scholar
  10. 10.
    Chen FF, Lin LN, Miao JX. Protective effect of Shenmai injection on lung injury induced by cardiac pulmonary bypass. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2009;29:414–7.PubMedGoogle Scholar
  11. 11.
    Cheng CW, Wu TX, Shang HC, Li YP, Altman DG, Moher D, Bian ZX, Group C-CF. CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration (traditional Chinese version). Ann Intern Med. 2017;167:W7–W20. Scholar
  12. 12.
    Schwarz N, Schonburg M, Kastaun S, Gerriets T, Kaps M. Cognitive deterioration after cardiosurgery. Nervenarzt. 2011;82(190):192–7. Scholar
  13. 13.
    Lombard FW, Mathew JP. Neurocognitive dysfunction following cardiac surgery. Semin Cardiothorac Vasc Anesth. 2010;14:102–10. Scholar
  14. 14.
    Nie K, Zhang Y, Wang L, Zhao J, Huang Z, Gan R, Li S, Wang L. A pilot study of psychometric properties of the Beijing version of Montreal cognitive assessment in patients with idiopathic Parkinson's disease in China. J Clin Neurosci. 2012;19:1497–500. Scholar
  15. 15.
    Nasreddine ZS. Montreal Cognitive Assessment. 2003/2012-10-4.
  16. 16.
    Yu J, Li J, Huang X. The Beijing version of the Montreal cognitive assessment as a brief screening tool for mild cognitive impairment: a community-based study. BMC Psychiatry. 2012;12:156. Scholar
  17. 17.
    Tan JP, Li N, Gao J, Wang LN, Zhao YM, Yu BC, Du W, Zhang WJ, Cui LQ, Wang QS, Li JJ, Yang JS, Yu JM, Xia XN, Zhou PY. Optimal cutoff scores for dementia and mild cognitive impairment of the Montreal cognitive assessment among elderly and oldest-old Chinese population. J Alzheimers Dis. 2015;43:1403–12. Scholar
  18. 18.
    Burkhart CS, Steiner LA. Can postoperative cognitive dysfunction be avoided? Hosp Pract (1995). 2012;40:214–23. Scholar
  19. 19.
    An LN, Yue Y, Guo WZ, Miao YL, Mi WD, Zhang H, Lei ZL, Han SJ, Dong L. Surgical trauma induces iron accumulation and oxidative stress in a rodent model of postoperative cognitive dysfunction. Biol Trace Elem Res. 2013;151:277–83. Scholar
  20. 20.
    Jones JD, Malaty I, Price CC, Okun MS, Bowers D. Health comorbidities and cognition in 1948 patients with idiopathic Parkinson's disease. Parkinsonism Relat Disord. 2012;18:1073–8. Scholar
  21. 21.
    Zheng F, Sheinberg R, Yee MS, Ono M, Zheng Y, Hogue CW. Cerebral near-infrared spectroscopy monitoring and neurologic outcomes in adult cardiac surgery patients: a systematic review. Anesth Analg. 2013;116:663–76. Scholar
  22. 22.
    Walther T, Dhein S, Ullmann C, Schneider K, Bilz T, Rastan A, Garbade J, Falk V, Emrich FC, Muth P, Mohr FW, Kostelka M. Cerebral protection during controlled hypoperfusion in a piglet model: comparison of moderate (25°C) versus deep (18°C) hypothermia at various flow rates using intraoperative measurements and ex vivo investigation. Thorac Cardiovasc Surg. 2013;61:546–52. Scholar
  23. 23.
    Sari A, Yamashita S, Ohosita S, Ogasahara H, Yamada K, Yonei A, Yokota K. Cerebrovascular reactivity to CO2 in patients with hepatic or septic encephalopathy. Resuscitation. 1990;19:125–34.CrossRefGoogle Scholar
  24. 24.
    Fordel E, Thijs L, Martinet W, Schrijvers D, Moens L, Dewilde S. Anoxia or oxygen and glucose deprivation in SH-SY5Y cells: a step closer to the unraveling of neuroglobin and cytoglobin functions. Gene. 2007;398:114–22.CrossRefGoogle Scholar
  25. 25.
    Li SQ, Li WB, Zhang M, Wu YZ, Hu YY. The role of neuroglobin in the neuroprotection of limb ischemic preconditioning in rats. Mol Neurobiol. 2013;47:197–208. Scholar
  26. 26.
    Barzo P, Marmarou A, Fatouros P, Hayasaki K, Corwin F. Biphasic pathophysiological response of vasogenic and cellular edema in traumatic brain swelling. Acta Neurochir Suppl. 1997;70:119–22.PubMedGoogle Scholar
  27. 27.
    Sun F, Mao X, Xie L, Greenberg DA, Jin K. Neuroglobin protein is upregulated in Alzheimer's disease. J Alzheimers Dis. 2013;36:659–63. Scholar
  28. 28.
    Ong SG, Hausenloy DJ. Hypoxia-inducible factor as a therapeutic target for cardioprotection. Pharmacol Ther. 2012;136:69–81. Scholar
  29. 29.
    Badawi Y, Ramamoorthy P, Shi H. Hypoxia-inducible factor 1 protects hypoxic astrocytes against glutamate toxicity. ASN Neuro. 2012;4:231–41. Scholar
  30. 30.
    Li D, Bai T, Brorson JR. Adaptation to moderate hypoxia protects cortical neurons against ischemia-reperfusion injury and excitotoxicity independently of HIF-1alpha. Exp Neurol. 2011;230:302–10. Scholar
  31. 31.
    Shao G, Gao CY, Lu GW. Alterations of hypoxia-inducible factor-1 alpha in the hippocampus of mice acutely and repeatedly exposed to hypoxia. Neurosignals. 2005;14:255–61.CrossRefGoogle Scholar
  32. 32.
    Di Giulio C, Zara S, Cataldi A, Porzionato A, Pokorski M, De Caro R. Human carotid body HIF and NGB expression during human development and aging. Adv Exp Med Biol 2012;758:265–271. doi: Scholar
  33. 33.
    Liu N, Yu Z, Xiang S, Zhao S, Tjarnlund-Wolf A, Xing C, Zhang J, Wang X. Transcriptional regulation mechanisms of hypoxia-induced neuroglobin gene expression. Biochem J. 2012;443:153–64. Scholar
  34. 34.
    Moore BW, McGregor D. Chromatographic and electrophoretic fractionation of soluble proteins of brain and liver. J Biol Chem. 1965;240:1647–53.PubMedGoogle Scholar
  35. 35.
    Giacoppo S, Bramanti P, Barresi M, Celi D, Foti Cuzzola V, Palella E, Marino S. Predictive biomarkers of recovery in traumatic brain injury. Neurocrit Care. 2012;16:470–7. Scholar
  36. 36.
    Zhang B, Huang Y, Su Z, Wang S, Wang S, Wang J, Wang A, Lai X. Neurological, functional, and biomechanical characteristics after high-velocity behind armor blunt trauma of the spine. J Trauma. 2011;71:1680–8. Scholar
  37. 37.
    Prohl J, Rother J, Kluge S, de Heer G, Liepert J, Bodenburg S, Pawlik K, Kreymann G. Prediction of short-term and long-term outcomes after cardiac arrest: a prospective multivariate approach combining biochemical, clinical, electrophysiological, and neuropsychological investigations. Crit Care Med. 2007;35:1230–7.CrossRefGoogle Scholar
  38. 38.
    Ramlawi B, Rudolph JL, Mieno S, Khabbaz K, Sodha NR, Boodhwani M, Levkoff SE, Marcantonio ER, Sellke FW. Serologic markers of brain injury and cognitive function after cardiopulmonary bypass. Ann Surg. 2006;244:593–601.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Reinsfelt B, Ricksten SE, Zetterberg H, Blennow K, Freden-Lindqvist J, Westerlind A. Cerebrospinal fluid markers of brain injury, inflammation, and blood-brain barrier dysfunction in cardiac surgery. Ann Thorac Surg. 2012;94:549–55. Scholar
  40. 40.
    McDonagh DL, Mathew JP, White WD, Phillips-Bute B, Laskowitz DT, Podgoreanu MV, Newman MF, Neurologic Outcome Research G. Cognitive function after major noncardiac surgery, apolipoprotein E4 genotype, and biomarkers of brain injury. Anesthesiology. 2010;112:852–9. Scholar
  41. 41.
    Lu LY, Zheng GQ, Wang Y. An overview of systematic reviews of shenmai injection for healthcare. Evid Based Complement Alternat Med. 2014;2014:840650. Scholar
  42. 42.
    Zhu J, Jiang Y, Wu L, Lu T, Xu G, Liu X. Suppression of local inflammation contributes to the neuroprotective effect of ginsenoside Rb1 in rats with cerebral ischemia. Neuroscience. 2012;202:342–51. Scholar
  43. 43.
    Yang CX, Liu JX, Sun ZL, Gao XQ, Deng L, Yuan QL. Effects of Ginsenoside RB1 on neural cell apoptosis and expressions of Bcl-2 and Bax in rats following subjected to cerebral ischemia-reperfusion. Sichuan da xue xue bao Yi xue ban. 2008;39:214–7.PubMedGoogle Scholar
  44. 44.
    Wang WX, Wang W, Chen KJ. Protective effect and mechanism of ginsenosides on central nerve system of animals. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005;25:89–93.PubMedGoogle Scholar

Copyright information

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Department of AnesthesiologyThe First Affiliated Hospital of Wenzhou Medical UniversityWenzhouChina
  2. 2.Wenzhou People’s HospitalWenzhouChina

Personalised recommendations